Vivo Bio Tech Ltd
Vivo Bio Tech Ltd (VIVOBIOT) last reported results for the quarter ended Jun 2026, with sales of ₹14.28 crore and net profit of ₹0.19 crore. The stock last traded at ₹14.9, a market capitalisation of ₹33.1 crore. Over the past 52 weeks the stock has ranged between ₹12.8 and ₹39. Figures are as of 9 Oct 2026 and are not real time.
Vivo Bio Tech Ltd share price and key metrics
- Current price
- ₹14.9
- Market cap
- ₹33.1 cr
- Book value
- ₹42
- ROE
- -2.24%
- ROCE
- 7.74%
- Dividend yield
- 0.00%
- 52w high / low
- 39.0/12.8
Metrics as of 9 Oct 2026. Not real time.
Track Vivo Bio Tech Ltd
Cruxal reads every Vivo Bio Tech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Vivo Bio Tech Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 1%
- TTM
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -134%
- 10 Years
- -10%
- 5 Years
- -28%
- 3 Years
- -26%
- 1 Year
- -61%
- 10 Years
- 6%
- 5 Years
- 2%
- 3 Years
- 1%
- Last Year
- -2%
Vivo Bio Tech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹14.28 cr, up 14.1% from ₹12.51 cr a year earlier. Net profit was ₹0.19 cr, down 85.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.04 | 12.21 | 12.29 | 12.51 | 13.11 | 13.51 | 14.2 | 14.28 |
| Expenses | 6.45 | 6.67 | 7.27 | 7.03 | 7.69 | 8.02 | 9.75 | 9.23 |
| Operating profit | 5.59 | 5.54 | 5.02 | 5.48 | 5.42 | 5.49 | 4.45 | 5.05 |
| OPM % | 46.43% | 45.37% | 40.85% | 43.80% | 41.34% | 40.64% | 31.34% | 35.36% |
| Other income | 4.63 | 0.01 | 0.15 | 0.14 | 0.13 | 0.14 | 0.03 | 0.06 |
| Interest | 2.06 | 1.84 | 1.68 | 1.5 | 1.47 | 1.4 | 1.48 | 1.24 |
| Depreciation | 2.29 | 2.25 | 2.25 | 2.64 | 2.57 | 2.66 | 2.75 | 3.53 |
| Profit before tax | 5.87 | 1.46 | 1.24 | 1.48 | 1.51 | 1.57 | 0.25 | 0.34 |
| Tax % | 10.73% | 43.84% | 14.52% | 9.46% | 42.38% | 20.38% | 2,164.00% | 44.12% |
| Net profit | 5.23 | 0.82 | 1.06 | 1.34 | 0.87 | 1.25 | -5.16 | 0.19 |
| EPS (₹) | 3.51 | 0.51 | 0.62 | 0.67 | 0.39 | 0.57 | -2.33 | 0.09 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vivo Bio Tech Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.13 | 47 | 55.83 | 55.35 | 51.78 | 51.39 | 52.23 | 45.45 | 46.67 | 53.33 | 55.1 |
| Operating profit | 7.62 | 10.89 | 9.51 | 12.47 | 17.8 | 16.09 | 21.84 | 21.26 | 20.56 | 21.51 | 20.41 |
| OPM % | 22.33% | 23.17% | 17.03% | 22.53% | 34.38% | 31.31% | 41.82% | 46.78% | 44.05% | 40.33% | 37.04% |
| Net profit | 2.5 | 3.12 | 2.25 | 4.44 | 5.68 | 2.2 | 2.65 | 2.53 | 7.28 | -1.71 | -2.85 |
| EPS (₹) | 2.67 | 3.17 | 1.82 | 3.45 | 4.23 | 1.54 | 1.78 | 1.70 | 4.24 | -0.77 | -1.28 |
TTM is the trailing twelve months to the most recent quarter.
Vivo Bio Tech Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 | 14.90 | 17.16 | 22.19 |
| Reserves | 3.22 | 9.46 | 14.92 | 20.14 | 29.11 | 32.87 | 36.97 | 39.50 | 60.74 | 70.97 |
| Borrowings | 27.06 | 25.12 | 21.68 | 24.37 | 30.96 | 67.44 | 62.39 | 73.06 | 54.02 | 67.38 |
| Other liabilities | 11.49 | 15.08 | 6.37 | 6.29 | 6.03 | 7.91 | 8.77 | 9.67 | 11.31 | 17.89 |
| Total liabilities | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 | 137.13 | 143.23 | 178.43 |
| Fixed assets | 28.57 | 27.66 | 30.01 | 34.99 | 52.05 | 95.17 | 88.87 | 80.37 | 88.24 | 123.03 |
| CWIP | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 | 9.21 | 12.84 | 4.81 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.91 |
| Other assets | 19.59 | 27.91 | 25.24 | 28.55 | 27.15 | 26.44 | 32.26 | 47.55 | 42.15 | 28.68 |
| Total assets | 51.12 | 59.51 | 55.32 | 63.69 | 79.52 | 122.48 | 123.03 | 137.13 | 143.23 | 178.43 |
As reported by the company. Total assets equal total liabilities by construction.
Vivo Bio Tech Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.66 | 11.11 | -0.78 | 8.61 | 14.18 | 16.64 | 14.83 | 15.52 | 11.83 | 34.93 |
| Cash from investing | -11.84 | -4.72 | -3.53 | -10.23 | -22.82 | -51.11 | -4.00 | -7.95 | -15.84 | -59.35 |
| Cash from financing | 6.83 | -3.43 | 0.72 | 2.09 | 8.78 | 35.02 | -11.18 | -7.56 | 3.90 | 24.57 |
| Net cash flow | -10.67 | 2.96 | -3.59 | 0.47 | 0.14 | 0.55 | -0.34 | 0.01 | -0.11 | 0.15 |
| Free cash flow | -17.50 | 6.39 | -4.31 | -1.62 | -8.64 | -34.47 | 10.83 | 7.57 | -4.01 | -2.51 |
| CFO / operating profit | -70% | 110% | -13% | 68% | 96% | 118% | 77% | 80% | 65% | 166% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Vivo Bio Tech Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12.37% | 15.18% | 9.55% | 13.82% | 18.78% | 9.29% | 11.02% | 9.94% | 9.04% | 7.74% |
| Debtor days | 82.03 | 91.48 | 54.98 | 69.11 | 51.39 | 85.37 | 86.52 | 94.76 | 87.98 | 80.42 |
| Inventory days | 204.47 | 289.48 | 255.75 | 451.13 | 672.29 | 312.99 | 429.70 | 831.44 | 491.08 | 365.90 |
| Days payable | 242.14 | 304.36 | 152.08 | 166.72 | 70.37 | 74.02 | 50.68 | 100.49 | 61.78 | 88.00 |
| Cash conversion cycle | 44.36 | 76.61 | 158.65 | 353.52 | 653.31 | 324.35 | 465.53 | 825.71 | 517.29 | 358.32 |
| Working capital days | 19.25 | -13.28 | 36.22 | 35.15 | 28.76 | 8.10 | 38.09 | 63.76 | 100.26 | -22.24 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Vivo Bio Tech Ltd shareholding pattern
Promoters held 30.62% at Jun 2026, down from 39.07% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.08% | 38.89% | 40.85% | 39.07% | 35.17% | 35.17% | 35.43% | 30.62% |
| Public | 57.91% | 61.12% | 59.16% | 60.94% | 64.84% | 64.84% | 64.58% | 69.39% |
| No. of shareholders | 19,545 | 21,167 | 21,935 | 21,865 | 21,647 | 21,622 | 21,427 | 21,225 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Vivo Bio Tech Ltd corporate filings
- Vivo Bio Tech Ltd encloses report on re-lodgement of physical share transfer requests for period ending September 2026Company Updatelow impact
Cruxal's analysis: The company has submitted a report regarding the re-lodgement of physical share transfer…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed
Read the full analysis - Vivo Bio Tech Limited's AGM Voting Results Confirm Re-appointment of Directors with Over 99% Support, Indicating Stable Shareholder ConfidenceAGM/EGMmedium impact
Cruxal's analysis: Vivo Bio Tech Limited reported that all resolutions at its 39th AGM held on September 30…
Read the full analysis - Vivo Bio Tech holds AGM on September 30, 2026; reappoints key directors with no immediate financial disclosuresCompany Updatelow impact
Cruxal's analysis: Vivo Bio Tech Limited conducted its 39th AGM via video conference on September 30, 2026…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed closure of trading window for quarter ended 30.09.2026
Read the full analysis - Vivo Bio Tech Ltd reports re-lodgement of physical share transfer requestsCompany Updatelow impact
Cruxal's analysis: Vivo Bio Tech Ltd has filed a routine disclosure regarding the re-lodgement of transfer…
Read the full analysis - Vivo Bio Tech Ltd processes annual report web links for shareholdersCompany Updatelow impact
Cruxal's analysis: Vivo Bio Tech Ltd has initiated the distribution of web links for its annual report to…
Read the full analysis - Vivo Bio Tech Limited Announces 39th Annual General Meeting Scheduled for September 30, 2026Company Updatelow impact
Cruxal's analysis: Vivo Bio Tech Limited has issued an intimation regarding its 39th Annual General Meeting…
Read the full analysis - Vivo Bio Tech Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Vivo Bio Tech Ltd has submitted its Annual Report for the financial year 2025-26. The…
Read the full analysis - Vivo Bio Tech Limited Announces 39th Annual General Meeting for FY 2025-2026AGM/EGMlow impact
Cruxal's analysis: Vivo Bio Tech Limited has issued a notice for its 39th Annual General Meeting (AGM)…
Read the full analysis - Vivo Bio Tech Ltd announces special window for re-lodgement of physical share transfer requestsCompany Updatelow impact
Cruxal's analysis: Vivo Bio Tech Ltd has published a newspaper notice regarding a special window for the…
Read the full analysis - Vivo Bio Tech Ltd announces expiry of outstanding warrantsCompany Updatelow impact
Cruxal's analysis: The company has formally disclosed the expiry of warrants, a routine corporate action…
Read the full analysis - Vivo Bio Tech Limited: Promoter Group Entity Divests 12 Lakh Equity Shares via Off-Market TransferInsider Trading / SASTmedium impact
Cruxal's analysis: Vivo Bio Tech Limited has witnessed a change in shareholding as Maxcell Communication…
Read the full analysis - Dwight Technologies Private Limited increases stake in Vivo Bio Tech Limited by 5.41% via off-market acquisitionInsider Trading / SASThigh impact
Cruxal's analysis: Dwight Technologies Private Limited has acquired 12 lakh equity shares of Vivo Bio Tech…
Read the full analysis - Vivo Bio Tech Limited: Promoter Group Entity P.K.L Solution Private Limited Divests 6 Lakh Equity SharesInsider Trading / SASTlow impact
Cruxal's analysis: Vivo Bio Tech Limited has reported a change in shareholding following an off-market…
Read the full analysis - Vivo Bio Tech Limited Announces Board Meeting Outcome Regarding AGM and Director Re-appointmentsOtherslow impact
Cruxal's analysis: Vivo Bio Tech Limited has announced that its 39th Annual General Meeting is scheduled for…
Read the full analysis - Vivo Bio Tech Ltd announces expiry of outstanding warrantsCompany Updatelow impact
Cruxal's analysis: The company has issued a formal notification regarding the expiry of warrants. This is a…
Read the full analysis - Vivo Bio Tech Ltd announces expiry of outstanding warrantsCompany Updatelow impact
Cruxal's analysis: The company has formally notified the exchange regarding the expiry of warrants. No…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.